NCT07182383View on ClinicalTrials.gov

Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

November 18, 2025

Study Completion Date

November 18, 2025

Conditions
Healthy Subjects
Interventions
DRUG

Bempedoic acid

"180 mg film coated tablet administered individually or as FDC~Component of FDC"

DRUG

Ezetimibe

"10 mg tablet administered individually or as FDC~Component of FDC"

DRUG

Rosuvastatin

"20 mg film coated tablet administered individually or as FDC~Component of FDC"

Trial Locations (1)

4250-449

Research Site, Porto

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT07182383 - Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin | Biotech Hunter | Biotech Hunter